Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study

Background Osimertinib is recommended for non‐small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients. This study assessed the potential effect of body surface area (BSA) and body mass index (B...

Full description

Bibliographic Details
Main Authors: Taihei Ono, Satoshi Igawa, Takahiro Ozawa, Masashi Kasajima, Mikiko Ishihara, Yasuhiro Hiyoshi, Seiichiro Kusuhara, Noriko Nishinarita, Tomoya Fukui, Masaru Kubota, Jiichiro Sasaki, Mitsufuji Hisashi, Masato Katagiri, Katsuhiko Naoki
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Thoracic Cancer
Subjects:
Body mass index
body surface area
non‐small cell lung carcinoma
osimertinib
progression‐free survival
Online Access:https://doi.org/10.1111/1759-7714.13018

Similar Items

Similar Items